explore -WSS

explore

author：explore 2025-10-02 20:06:22 - browse：94325

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

leisure time

hotspot

WSS

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

A timeline of the missing Titanic tourist submersible

Change Healthcare can notify patients about the breach, HHS says

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

A timeline of the missing Titanic tourist submersible

Noem? Reynolds? A very early look at the Republican 'veepstakes'

focus

explore

focus

Medical records are filled with copy

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

ChatGPT in medicine: STAT answers readers' burning questions

3 killed, 8 injured in late

23andMe had bad news about my health. I wish a person had delivered it

Ionis drug prevents swelling attacks due to hereditary angioedema

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Innovation in antibiotics is ailing. 'Brain drain' may kill it

BioMarin wins approval for gene therapy to treat hemophilia A

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

hotspot

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca says CAR

A timeline of the missing Titanic tourist submersible

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

A timeline of the missing Titanic tourist submersible

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

knowledge

leisure time

hotspot

Wikipedia